Development and validation of the Asthma Life Impact Scale (ALIS) - 20/08/11
, Stephen P. McKenna a , Lynda C. Doward a, Robin Pokrzywinski b, Dennis Revicki b, Cameron Hunter c, G. Alastair Glendenning d
Corresponding author. Galen Research, Enterprise House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, United Kingdom. Tel.: +44 161 226 4446; fax: +44 161 226 4478.Summary |
Background |
Current asthma patient-reported outcome (PRO) measures focus on symptoms and functioning and may not capture the holistic impact of asthma on the quality of life of the patient.
Objective |
To develop a PRO measure capturing the overall impact of asthma on patient's quality of life.
Methods |
Items for the Asthma Life Impact Scale (ALIS) were generated from patients with asthma during interviews in the UK and focus groups in the US. The ALIS was tested with UK and US asthma patients during cognitive debriefing interviews and included in large, two-administration, validation studies in the UK and US.
Results |
Issues raised by asthma patients during interviews (n = 39 patients) and focus groups (n = 16 patients) were included in the draft ALIS. Cognitive debriefing interviews with 29 UK and US asthma patients showed that the scale was relevant and comprehensive. 140 UK and 185 US asthma patients participated in the validation study. The analysis showed that the ALIS measures a single construct, namely the overall impact of asthma on patients' quality of life. Internal consistency (Cronbach's Alpha) was high (UK = 0.94; US = 0.92) as was test-retest reliability (UK = 0.93; US = 0.83). Patients reporting worse general health or more severe asthma had significantly higher ALIS scores (p < 0.001) (indicating greater negative impact of asthma). Correlations with the Asthma Quality of Life Questionnaire were moderate to high.
Conclusions |
The final 22-item ALIS is unidimensional, reliable and valid, and a valuable tool for comprehensively assessing the holistic impact of asthma from the patient's perspective.
Le texte complet de cet article est disponible en PDF.Keywords : Asthma, Quality of life, Patient-reported outcome, Questionnaire
Abbreviations : ALIS, AQLQ, IRT, RUMM, QoL, PRO
Plan
Vol 104 - N° 5
P. 633-643 - mai 2010 Retour au numéro
Article précédent
- Association of the CCR3 gene polymorphism with aspirin exacerbated respiratory disease
- Seung-Hyun Kim, Eun-Mi Yang, Haet-Nim Lee, Gil-Soon Choi, Young-Min Ye, Hae-Sim Park
- Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study
- J. Christian Virchow, Anish Mehta, Li Ljungblad, Harald Mitfessel, the MONICA study group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?